Kymera Therapeutics (NASDAQ:KYMR) Price Target Cut to $52.00 by Analysts at Oppenheimer

Kymera Therapeutics (NASDAQ:KYMR) had its price target reduced by Oppenheimer from $53.00 to $52.00 in a report published on Friday, Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages also recently weighed in on KYMR. Stifel Nicolaus raised their price target on Kymera Therapeutics from $35.00 to $55.00 and gave the company a buy rating in a report on Friday, February 23rd. Wolfe Research began coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a peer perform rating on the stock. Truist Financial increased their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a buy rating in a report on Friday, March 1st. JPMorgan Chase & Co. upped their price objective on Kymera Therapeutics from $34.00 to $47.00 and gave the company an overweight rating in a research report on Friday, February 23rd. Finally, Piper Sandler lifted their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an overweight rating in a report on Tuesday, February 27th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics has an average rating of Moderate Buy and a consensus target price of $41.10.

Kymera Therapeutics Trading Up 3.0 %

Kymera Therapeutics stock traded up $1.10 on Friday, hitting $37.40. 529,668 shares of the stock traded hands, compared to its average volume of 508,411. Kymera Therapeutics has a 1 year low of $9.60 and a 1 year high of $45.31. The firm has a market cap of $2.29 billion, a P/E ratio of -14.90 and a beta of 2.31. The business’s fifty day simple moving average is $38.52 and its 200 day simple moving average is $29.33.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 37.83%. The business had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. Kymera Therapeutics’s quarterly revenue was up 8.4% on a year-over-year basis. As a group, analysts predict that Kymera Therapeutics will post -3.15 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the completion of the sale, the insider now directly owns 4,925,812 shares in the company, valued at approximately $211,071,044.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of Kymera Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the transaction, the insider now owns 4,925,812 shares in the company, valued at approximately $211,071,044.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total value of $4,860,250.70. Following the completion of the sale, the insider now owns 4,676,075 shares of the company’s stock, valued at approximately $197,470,647.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 474,051 shares of company stock valued at $19,624,211. 16.67% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its stake in Kymera Therapeutics by 33.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after buying an additional 1,310 shares in the last quarter. Quest Partners LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $78,000. Arizona State Retirement System purchased a new stake in shares of Kymera Therapeutics during the third quarter worth about $142,000. China Universal Asset Management Co. Ltd. raised its stake in Kymera Therapeutics by 352.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Kymera Therapeutics in the 3rd quarter worth approximately $185,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.